Nektar Therapeutics Earnings Preview
Portfolio Pulse from Benzinga Insights
Nektar Therapeutics (NASDAQ:NKTR) is scheduled to release its quarterly earnings report on March 4, 2024, with an expected EPS of $-0.21. Despite beating the EPS estimate last quarter by $0.01, NKTR's stock dropped by 8.76% the following day. Historically, the company's earnings performance has led to mixed stock price reactions. Currently trading at $0.71, NKTR shares have declined by 49.2% over the last year, indicating a bearish outlook among long-term shareholders.
March 01, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Nektar Therapeutics is expected to report an EPS of $-0.21 for the upcoming quarter. Historical data shows mixed reactions to past earnings, with a significant 49.2% decline in stock price over the last year.
Given NKTR's history of stock price decline following earnings reports, especially with a 49.2% decrease over the last year, the upcoming earnings report is likely to have a negative short-term impact. The anticipation of the earnings guidance, which could influence investor sentiment, adds to the uncertainty. However, the consistent past performance of beating EPS estimates could provide some positive outlook, but the overall trend suggests a bearish sentiment.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100